Your browser doesn't support javascript.
loading
Arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy.
Gasperetti, Alessio; James, Cynthia A; Carrick, Richard T; Protonotarios, Alexandros; Te Riele, Anneline S J M; Cadrin-Tourigny, Julia; Compagnucci, Paolo; Duru, Firat; van Tintelen, Peter; Elliot, Perry M; Calkins, Hugh.
Afiliação
  • Gasperetti A; Division of Cardiology, Department of Medicine, Johns Hopkins University, Blalock 545, 600 N. Wolfe St., Baltimore, MD 21287, USA.
  • James CA; Department of Genetics, University Medical Center Utrecht, University of Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.
  • Carrick RT; Department of Medicine, Division of Cardiology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, Utrecht, The Netherlands.
  • Protonotarios A; Division of Cardiology, Department of Medicine, Johns Hopkins University, Blalock 545, 600 N. Wolfe St., Baltimore, MD 21287, USA.
  • Te Riele ASJM; Division of Cardiology, Department of Medicine, Johns Hopkins University, Blalock 545, 600 N. Wolfe St., Baltimore, MD 21287, USA.
  • Cadrin-Tourigny J; Department of Cardiology, UCL Institute of Cardiovascular Science, London, UK.
  • Compagnucci P; Department of Medicine, Division of Cardiology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, Utrecht, The Netherlands.
  • Duru F; Cardiovascular Genetics Center, Montreal Heart Institute, Université de Montréal, Montréal, QC, Canada.
  • van Tintelen P; Cardiology and Arrhythmology Clinic, Marche University Hospital, Ancona, Italy.
  • Elliot PM; Department of Cardiology, Arrhythmia Unit, University Heart Center, University Hospital Zurich, Zurich, Switzerland.
  • Calkins H; Department of Genetics, University Medical Center Utrecht, University of Utrecht, Heidelberglaan 100, Utrecht, The Netherlands.
Europace ; 25(11)2023 11 02.
Article em En | MEDLINE | ID: mdl-37935403
ABSTRACT
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable cardiomyopathy characterized by a predominantly arrhythmic presentation. It represents the leading cause of sudden cardiac death (SCD) among athletes and poses a significant morbidity threat in the general population. As a causative treatment for ARVC is still not available, the placement of an implantable cardioverter defibrillator represents the current cornerstone for SCD prevention in this setting. Thanks to international ARVC-dedicated efforts, significant steps have been achieved in recent years towards an individualized, patient-centred risk stratification approach. A novel risk calculator algorithm estimating the 5-year risk of arrhythmias of patients with ARVC has been introduced in clinical practice and subsequently validated. The purpose of this article is to summarize the body of evidence that has allowed the development of this tool and to discuss the best way to implement its use in the care of an individual patient.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desfibriladores Implantáveis / Displasia Arritmogênica Ventricular Direita Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desfibriladores Implantáveis / Displasia Arritmogênica Ventricular Direita Idioma: En Ano de publicação: 2023 Tipo de documento: Article